{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:44:07Z","timestamp":1764175447049,"version":"3.37.3"},"reference-count":41,"publisher":"Informa UK Limited","issue":"15","funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012495","name":"Spondylitis Association of America","doi-asserted-by":"publisher","award":["Bruckel Awards"],"award-info":[{"award-number":["Bruckel Awards"]}],"id":[{"id":"10.13039\/100012495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.2217\/imt-2023-0032","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T08:18:32Z","timestamp":1694074712000},"page":"1227-1237","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Upadacitinib for the Treatment of Axial Spondyloarthritis"],"prefix":"10.1080","volume":"15","author":[{"given":"Navya","family":"George","sequence":"first","affiliation":[{"name":"Internal Medicine Residency Program, Boston University Medical Center, Boston, MA 02118, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-2450","authenticated-orcid":false,"given":"Jean W","family":"Liew","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-1515","authenticated-orcid":false,"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA"},{"name":"VA Boston Healthcare System, Boston, MA 02130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X18773726"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"e_1_3_2_6_1","unstructured":"Spondylitis Association of America\n. Upadacitinib (Rinvoq) approved for non-radiographic axial spondyloarthritis (2022). https:\/\/spondylitis.org\/research-new\/upadacitinib-rinvoq-approved-for-non-radiographic-axial-spondyloarthritis\/#:\u223c:text=Upadacitinib%20(Rinvoq)%20has%20become%20the nr%2DaxSpA)%20in%20adults.&text=Upadacitinib%20was%20also%20approved%20for PsA)%20in%20December%20of%202021"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00761-z"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0132-y"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101811"},{"issue":"24","key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2146\/news120088","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor K","year":"2012","unstructured":"Traynor K . FDA approves tofacitinib for rheumatoid arthritis. Am. J. Health Syst. Pharm.69(24), 2120 (2012).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010037"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01211-z"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.2006183"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2038134"},{"key":"e_1_3_2_17_1","unstructured":"Cangemi L\n. RINVOQ \u00ae (upadacitinib) approved by US FDA as an oral treatment for adults with active ankylosing spondylitis (2022). https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-approved-by-us-fda-as-an-oral-treatment-for-adults-with-active-ankylosing-spondylitis.htm"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab740"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_3_2_22_1","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study","volume":"10","author":"McInnes IB","year":"2023","unstructured":"McInnes IB , KatoK , MagreyMet.al Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol. Ther.10, 275\u2013292 (2023).","journal-title":"Rheumatol. Ther."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00305-z"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0130"},{"issue":"2","key":"e_1_3_2_26_1","first-page":"ii49","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease PJ","year":"2005","unstructured":"Mease PJ . Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis.64(Suppl. 2), ii49\u2013ii54 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41911"},{"issue":"2","key":"e_1_3_2_30_1","doi-asserted-by":"crossref","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"van der Heijde D","year":"2022","unstructured":"van der Heijde D , DeodharA , MaksymowychWPet.al Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open8(2), e002280 (2022).","journal-title":"RMD Open"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052449"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40798"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab294"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42250"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216761"},{"key":"e_1_3_2_41_1","unstructured":"US FDA\n. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate (2019). www.fda.gov\/media\/120485\/download"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.01.014"},{"key":"e_1_3_2_43_1","unstructured":"Taylor N\n. Gilead stops 3 filgotinib trials pending FDA feedback on faltering JAK1 inhibitor (2020). www.fiercebiotech.com\/biotech\/gilead-stops-3-filgotinib-trials-pending-fda-feedback-faltering-jak1-inhibitor"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2023-0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:06:04Z","timestamp":1715943964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2023-0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.2217\/imt-2023-0032"],"URL":"https:\/\/doi.org\/10.2217\/imt-2023-0032","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"type":"print","value":"1750-743X"},{"type":"electronic","value":"1750-7448"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}